舒利迭在治疗慢性阻塞性肺病中的辅助作用

The Effect of Salmeterol Xinafoate and Fluticasone Propionate Powder for in Treating Chronic Obstructive Pulmonary Disease

目的探讨舒利迭治疗慢性阻塞性肺病的作用。方法选择100例慢性阻塞性肺病(COPD)患者为研究对象,并随机分为试验组和对照组。两组均予以常规治疗,试验组在常规治疗基础上加舒利迭吸入治疗。结果1)两组患者治疗后肺功能各项指标均较治疗前升高(P<0.05),表明经治疗肺功能均有所改善。两组各项指标治疗前后差值均表现为试验组高于对照组(P<0.05)。2)两组患者治疗后,PaO_2均升高(P<0.05),PaCO_2(P<0.05)均下降,两组治疗前后PaO_2及PaCO_2差值,均以试验组高于对照组(P<0.05)。3)试验组对症状体征改善的有效率为66%,对照组为62%(P>0.05)。4)用药期间,试验组有3例出现口干及咽喉不适,均自行缓解。对照组无明显不良反应发生。结论舒利迭对慢性阻塞性肺病(COPD)疗效好,且安全,值得在临床上推广应用。

Objective To study the effect of Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation on chronic obstructive pulmonary disease. Methods The patients with COPD who were treated in our hospital during January 2007 to December 2008 were selected as the study objects. All of them were divided into 2 groups： trial group and control group. All patients were treated with conventional therapy, and the patients in treatment group were treated with Salmeterol Xinafoate and Futicasone Propionate Powder for Inhalation additionly. Results 1 ） Every parameter of lung function of the patients in both groups increased after treated （ P 〈 0. 05 ）. The value changes of every parameter in treatment group were significantly higher than those in the control group （ P 〈 0.05 ）. 2 ） After treated, the level of PaO2 of both groups increased, while the level of PaCO2 decreased. Than value changes of the two parameters of treatment group were higher than those of the control group. 3） The efficient rate for symptom and body sign recovery of trial group was higher than that of control group. [trial group：66 % ; control group： 62 % ; P〉0.05）. 4） During the period of treatment, three patients manifested adverse drug reaction and recovered without any therapy. Conclusions Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was a safe and effective drug for COPD patients.